Australia: High Court upholds earlier decision that AstraZeneca's cholesterol-lowering patent is obvious

Last Updated: 8 September 2015
Article by Natalie Shoolman

In a closely-watched patent decision, the High Court has unanimously dismissed AstraZeneca's appeal concerning its low-dose patent for the cholesterol-lowering drug rosuvastatin (AstraZeneca AB v Apotex Pty Ltd [2015] HCA 30).

In doing so, the High Court has adopted a common sense approach to the way in which prior art publications can be used to attack a patent based on lack of inventive step. It held that the invention claimed in AstraZeneca's "low dose patent" was obvious when considered in the light of the common general knowledge, taken together with either of two prior art publications.

The origins of the dispute

The patent in suit (the "low dose patent") related to the single, once-daily oral administration of 5mg to 10mg of rosuvastatin, a drug used in the treatment of high cholesterol (or hypercholesterolemia). Rosuvastatin is marketed by AstraZeneca under the brand name "Crestor".

Both the trial judge, and a special five member bench of the Full Federal Court on appeal, had found that the low dose patent was invalid as it did not involve an inventive step. AstraZeneca was granted special leave to appeal to the High Court.

Question of obviousness

The basis upon which inventive step is assessed is governed by sections 7(2) and 7(3) of the Patents Act 1990. The interpretation and operation of these two provisions was the central issue addressed by the High Court in its judgment.

In essence, section 7(2) provides that an invention involves an inventive step when compared with the prior art base, unless the invention would have been obvious to a relevantly skilled person in light of the common general knowledge at the priority date of the patent. Section 7(3) permits certain documents to be combined with the common general knowledge in limited circumstances.

Does section 7(3) require that each document be considered separately to determine relevance?

AstraZeneca argued that, in determining whether prior art information was relevant for the purposes of section 7(3), each document must be considered separately. It contended that it was impermissible for the person skilled in the art to compare multiple documents that they had ascertained and to select from these the relevant document or documents to be used for answering the question of obviousness under section 7(2).

The High Court emphatically rejected this approach, holding that there is nothing impermissible in such an exercise of selection. Justices Gageler and Keane noted that "[n]othing in s7(3) suggests that the notional skilled addressee may not trawl through multiple documents, discarding the irrelevant and retaining the useful, as part of the ascertainment of relevant information".

It noted that section 7(3) is directed towards the identification of prior art that can be used for the purposes of section 7(2). Section 7(2) is directed to how that information is used. What section 7(2) requires is that, where multiple pieces of prior art are available and capable of being regarded as relevant, each must be considered separately, together with the common general knowledge, to answer the statutory question as to whether the invention is obvious.

The purpose of the requirement in section 7(2) that documents be considered separately is directed at preventing what is called "mosaicing". Mosaicing occurs where select pieces of information from a number of prior publications are assembled such that the mosaic of information reveals what is claimed in the patent. Such an approach is impermissible in relation to patents filed before April 2002 (as the low-dose patent was). However, in the present case, the document under consideration by the High Court was a single document. AstraZeneca had sought to rely on the requirement that documents be considered separately to impugn a single piece of prior art selected from multiple documents on the basis of relevance. AstraZeneca's position on this point was rejected by all five justices of the High Court.

Must each document qualifying as relevant be considered separately under section 7(2)?

In addition, AstraZeneca submitted that not only must each document qualifying as relevant be considered separately, but that each must be considered under section 7(2). None may be discarded. In these circumstances, a person skilled in the art would have had more than one candidate drug to choose from as the prior art documents identified by the expert witnesses as relevant did not relate solely to rosuvastatin. On this basis, AstraZeneca submitted that the claim of obviousness must fail because the expert witnesses did not discuss what they would do in such a situation.

This submission was rejected by the Court based on the expert evidence - the hypothetical question did not arise, as the respondents' experts selected rosuvastatin as the candidate they would proceed with.

The High Court finds the claimed invention was obvious

The Court accepted that the prior art relied upon by the respondent generic companies would have been regarded as relevant by the hypothetical person skilled in the art based on the expert evidence before the Court. The Court then considered the operation of section 7(2) and whether the invention was obvious to a person skilled in the art armed with the common general knowledge and the relevant prior art. The High Court upheld the decisions of the trial judge and the Full Court that the invention claimed in the patent was obvious, based on the expert evidence that it had before it.

Issues the Court did not address

Having found that the invention claimed in the low dose patent was obvious, the High Court did not consider the other issues agitated.

One of the most interesting of those issues related to the appropriate "starting point" for assessing whether a claimed invention involves an inventive step. The approach to this issue can be a significant determinant of the outcome of an inventive step fight. Using the present case as an example, does one ask:

  • whether it is possible to invent a new method of treating high cholesterol; or, alternatively
  • whether it is possible to invent a new method of treating high cholesterol using rosuvastatin?

In other words, is the use of rosuvastatin a "given"?

As the High Court declined to express any opinion on this issue, the law concerning the appropriate "starting point" when assessing inventive step under the Patents Act 1990 remains as stated by the Full Federal Court in this case (AstraZeneca AB v Apotex Pty Ltd [2014] FCAFC 99): the inventive step must be assessed by reference to the common general knowledge of the person skilled in the art, whether alone or taken together with the relevant prior art information permitted to be considered under section 7(3).

The description of the invention in the patent specification, including any problem that the invention is explicitly or implicitly directed at solving, is not to be considered unless:

  • this formed part of the common general knowledge of the person skilled in the art; or
  • it is information of a kind permitted to be taken into account together with common general knowledge pursuant to section 7(3).

In other words, as Justice Jessup put it in the Full Federal Court in this case, in circumstances where it was held that rosuvastatin did not form part of the common general knowledge and the selection of rosuvastatin was an integer of the invention claimed, the question for determining whether the invention was obvious is: "given a patient suffering from hypercholesterolemia, would the treatment of him or her with rosuvastatin in the claimed doses be obvious?", rather than "given rosuvastatin, would the administration of it at the claimed doses be obvious?".

Under the Patents Act 1952, the Full Court's reasoning in Apotex Pty Ltd v Sanofi-Aventis (2009) 82 IPR 416 regarding "starting point" remains the law as it was not formally overruled by the expanded bench of the Full Court in this case (and was not addressed at all by the High Court).

Implications of the High Court's decision

The High Court has adopted a sensible interpretation of the operation of sections 7(2) and 7(3) of the Patents Act 1990 that provides certainty for innovators and generic companies.

The judgment means that AstraZeneca's defence of Crestor has ended in defeat.

There was an interlocutory injunction in place until the final decision at first instance dissolved the injunction. In exchange for the injunction, AstraZeneca gave the usual undertaking as to damages to the generic parties. The generic parties may now make a claim on the undertaking for losses they suffered by reason of their generic products having been kept off the market due to the interlocutory injunction, while the litigation took its course.

The Commonwealth may also seek to make a claim on the undertaking as to damages for the costs it incurred during this period when the generics were prevented from obtaining listing on the Schedule of Pharmaceutical Benefits, as it has done in at least two proceedings currently on foot in the Federal Court (Alphapharm v Wyeth and Apotex Pty Ltd v Sanofi-Aventis).

Clayton Utz communications are intended to provide commentary and general information. They should not be relied upon as legal advice. Formal legal advice should be sought in particular transactions or on matters of interest arising from this bulletin. Persons listed may not be admitted in all states and territories.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.